By Connor Hart
Scholar Rock named David Hallal as its chief executive, succeeding Jay Backstrom.
Hallal, who has served as chairman of the biopharmaceutical company's board since 2017, previously spent more than a decade holding executive positions at Alexion.
In the transition, Backstrom will move an advisory role and continue working with the company's executive team and board, Scholar Rock said Monday.
With the CEO transition, Scholar Rock said that Vikas Sinha will join as chief financial officer, R. Keith Woods has been appointed chief operating officer and Akshay Vaishnaw was named president of research and development.
Sinha formerly served as chief financial officer of Alexion and ElevateBio.
In the chief operating role, Woods will focus on evolving the company into what it called a fully-integrated global enterprise. He previously was chief operating officer of Argenx.
Vaishnaw will serve in the newly created role of president of research and development after previously serving as president of Alnylam.
Shares fell 1.5%, to $32.31, in pre-market trading.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
April 28, 2025 07:10 ET (11:10 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.